DMAC Logo

DiaMedica Therapeutics Inc. (DMAC) 

NASDAQ
Market Cap
$225.35M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
69 of 960
Rank in Industry
52 of 550

Largest Insider Buys in Sector

DMAC Stock Price History Chart

DMAC Stock Performance

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory …

Insider Activity of DiaMedica Therapeutics Inc.

Over the last 12 months, insiders at DiaMedica Therapeutics Inc. have bought $6M and sold $0 worth of DiaMedica Therapeutics Inc. stock.

On average, over the past 5 years, insiders at DiaMedica Therapeutics Inc. have bought $3.41M and sold $3.53M worth of stock each year.

Highest buying activity among insiders over the last 12 months: STAHLBERG JAN (10 percent owner) — $3M. Von Koch Thomas (10 percent owner) — $3M.

The last purchase of 1,200,000 shares for transaction amount of $3M was made by Von Koch Thomas (10 percent owner) on 2024‑06‑28.

List of Insider Buy and Sell Transactions, DiaMedica Therapeutics Inc.

2024-06-28Purchase10 percent owner
1.2M
2.6697%
$2.50$3M0.00%
2024-06-28Purchase10 percent owner
1.2M
2.6697%
$2.50$3M0.00%
2023-11-16PurchaseChief Business Officer
20,000
0.0542%
$2.46$49,200+23.43%
2023-06-23Purchase10 percent owner
1.47M
4.4481%
$3.40$5M-33.18%
2023-06-23PurchaseChief Business Officer
38,364
0.1334%
$3.91$150,003-33.18%
2023-06-23Purchasedirector
65,000
0.2261%
$3.91$254,150-33.18%
2023-06-23Purchasedirector
38,363
0.1334%
$3.91$149,999-33.18%
2023-06-23PurchasePresident and CEO
12,787
0.0445%
$3.91$49,997-33.18%
2023-06-23PurchaseCFO and Secretary
10,000
0.0348%
$3.91$39,100-33.18%
2023-06-23Purchasedirector
12,787
0.0445%
$3.91$49,997-33.18%
2023-04-10PurchaseChief Business Officer
468,750
1.8065%
$1.60$750,000+79.62%
2022-12-09Purchasedirector
37,079
0.1402%
$1.43$53,023+57.34%
2022-12-08Purchasedirector
20,000
0.0735%
$1.40$28,000+55.90%
2022-12-07Purchasedirector
22,574
0.086%
$1.40$31,604+61.15%
2022-12-06Purchasedirector
2,300
0.0083%
$1.35$3,105+57.39%
2022-12-05Purchasedirector
35,000
0.14%
$1.39$48,493+69.08%
2022-12-02Saledirector
2.86M
9.0121%
$1.24$3.53M+47.97%
2022-12-02Purchasedirector
2.86M
9.0121%
$1.24$3.53M+47.97%
2022-12-01Purchasedirector
46,952
0.1775%
$1.20$56,334+82.08%
2022-11-30Purchasedirector
2,970
0.0112%
$1.19$3,534+82.77%

Insider Historical Profitability

17.55%
Von Koch Thomas10 percent owner
5526435
12.9241%
$5.2731+7.4%
STAHLBERG JAN10 percent owner
5221608
12.2113%
$5.2710
TomEnterprise AB
2855827
6.6786%
$5.2710+16.67%
Wambeke David J.Chief Business Officer
527114
1.2327%
$5.2730+23.22%
Giuffre Randall Michaeldirector
360355
0.8427%
$5.27100+49.77%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$2.81M2.671.01M+26.35%+$585,442.28<0.0001
Leon G. Cooperman$2.45M2.33883,6230%+$00.1
First Manhattan Co.$2.35M2.24850,038+640.81%+$2.04M0.01
Paragon Associates Paragon Associates Ii Joint Venture$1.39M1.32500,0000%+$02.47
Geode Capital Management$662,841.000.63239,235+9.35%+$56,679.58<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.